For the Inventor, By the Inventor

Enter assignee name

Chicago, IL, United States of America

G.d. Searle LLC

USPTO Granted Patents = 33

% Expired Patents = 39.4

CIPO Patents = 1

Trademarks = 14

Forward Citations = 182

Loading Chart...

Loading Chart...

90 inventors (with patents filed for the assignee):

Daniel P Getman (14 out of 170 patents)

John Nicholas Freskos (14 out of 126 patents)

Gary A DeCrescenzo (13 out of 139 patents)

4. John Jeffrey Talley (12 out of 228 patents)

5. Michael L Vazquez (11 out of 131 patents)

6. Richard A Mueller (9 out of 211 patents)

7. James A Sikorski (8 out of 130 patents)

8. Robert M Heintz (6 out of 56 patents)

9. Deborah E Bertenshaw (6 out of 32 patents)

10. Kevin C Glenn (6 out of 18 patents)

11. Joseph J McDonald (4 out of 53 patents)

12. Srinivasan Raj Nagarajan (3 out of 52 patents)

13. Bradley T Keller (2 out of 11 patents)

14. Daniel Paul Becker (2 out of 59 patents)

15. Balekudru Devadas (2 out of 68 patents)

Core Competencies:

Retroviral Protease Inhibitors

Inflammation Treatments

Cardiovascular Indications

Sulfonamides

Amino Acids

Bile Acid Transport

Drug Delivery Systems

Cholesteryl Ester Transfer Protein

Hypertension Treatments

Formulation Techniques

Micronized Compositions

Fusion Proteins

33 patents: Sort by Forward Citations

1. RE44048 - 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder (2013-03-04),

2. RE43802 - α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors (2012-11-12),

3. RE43596 - α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors (2012-08-20),

4. RE42889 - α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors (2011-10-31),

5. 7829564 - α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors (2010-11-09),

6. 7531538 - α- and β-Amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors (2009-05-12),

7. 7339078 - Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors (2008-03-04),

8. 7320983 - α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors (2008-01-22),

9. 7297793 - Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors (2007-11-20),

10. 7226932 - Self-emulsifying drug delivery system (2007-06-05),

11. 7226757 - Formulation, solubilization, purification, and refolding of tissue factor pathway inhibitor (2007-06-05),

12. 7157101 - Micronized eplerenone compositions (2007-01-02),

13. 7132437 - Renal-selective biphenylalkyl 1H-substituted-1,2,4-triazole angiotensin II antagonists for treatment of hypertension (2006-11-07),

14. 7022672 - Formulation, solubilization, purification, and refolding of tissue factor pathway inhibitor (2006-04-04),

15. 7012094 - Substituted furans and furanones for the treatment of inflammation (2006-03-14),

G.d. Searle LLC, headquartered in Chicago, IL, is a prominent player in the pharmaceutical industry, focusing on the development and manufacturing of innovative healthcare solutions. The company specializes in a range of therapeutic areas, including pain management, oncology, and gastrointestinal health. With a commitment to research and development, G.d. Searle leverages advanced technologies to create effective medications that address unmet medical needs, enhancing patient outcomes and quality of life.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

33 Patents

#139 in Chicago, IL

#562 in Illinois

#10,288 in US

#20,112 in the World

Chicago, IL, United States of America

G.d. Searle LLC

Forward Citations = 182

90 inventors:

Daniel P Getman (14 out of 170 patents)

John Nicholas Freskos (14 out of 126 patents)

Gary A DeCrescenzo (13 out of 139 patents)

4. John Jeffrey Talley (12 out of 228 patents)

5. Michael L Vazquez (11 out of 131 patents)

Please report any incorrect information to [email protected]

Loading…